<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408563</url>
  </required_header>
  <id_info>
    <org_study_id>11-085</org_study_id>
    <nct_id>NCT01408563</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Double Umbilical Cord Blood Transplantation</brief_title>
  <official_title>A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will use two cord blood units for transplantation using a reduced intensity
      regimen rather than using intense doses of chemotherapy and radiation therapy. Two cord blood
      units (double cord blood) are being used, as the numbers of blood cells in one unit are too
      few to allow successful growth of these cells.

      Because the risk of infection, particularly virus infection, is high after double cord blood
      transplant, this study seeks to reduce the rise of virus infection by using a reduced
      intensity regimen without a medicine called antithymocyte globulin (ATG), as used in prior
      cord blood transplants. Subjects will receive two chemotherapy drugs, melphalan and
      fludarabine, and low dose of total body radiation (one treatment) instead of the ATG. The
      number of patients with virus infections in this study will be compared to our prior
      experience using the ATG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive their transplants as in-patients.

        -  IV-Catheter

             -  one or two IV catheters will be placed on the day of hospital admission

        -  Conditioning

             -  Fludarabine IV six days before transplant (days -7, -6, -5. -4, -3, -2)

             -  Melphalan IV (day -1)

             -  Total body radiation on day 0 (same day as transplant)

        -  Immunosuppressive Therapy

             -  Tacrolimus and sirolimus beginning day -3, daily for 6-9 months post-transplant.
                Given IV as in-patient, orally as out-patient

        -  Infusion of Cord Blood units

             -  2 cord blood units IV on Day 0 Routine post-transplant supportive care will be
                provided
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One year significant viral infection rate</measure>
    <time_frame>2.5 years</time_frame>
    <description>To determine the one year significant viral infection rate (viral infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of primary graft failure</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Grade II-IV and Grade III-IV acute GVHD at 100 days</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of chronic GVHD</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day treatment related mortality</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution - CD4 count at 12 months</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free and overall survival at 1 and 2 years from transplantation</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-transplant lymphoma</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombopoietin levels after transplant</measure>
    <time_frame>2.5 years</time_frame>
    <description>Optional correlate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive same therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day IV x 6 days</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100 mg/m2/day IV x 1 day</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Radiation</intervention_name>
    <description>200 cGy on Day 0</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood</intervention_name>
    <description>2 cord blood units IV</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologic malignancy for whom allogeneic stem cell transplantation is deemed
             clinically appropriate

          -  Appropriate candidate for reduced intensity regimen, according to the treating
             physician

          -  Lack of 6/6/ or 5/6 HLA-matched related, 8/8/ HLA-matched unrelated donor, or
             unrelated donor not available with a time frame necessary to perform a potentially
             curative stem cell transplant

          -  Able to comply with the requirements for care after allogeneic stem cell
             transplantation

        Exclusion Criteria:

          -  Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular
             dysfunction

          -  Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic
             restrictive lung disease

          -  Renal disease

          -  Hepatic disease

          -  Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other
             neuropsychiatric abnormalities believed to preclude transplantation

          -  HIV-positive

          -  Uncontrolled infection

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Zachariah Michael DeFilipp</investigator_full_name>
    <investigator_title>Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>lymphoma</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelodysplastic disorder</keyword>
  <keyword>aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

